Australia markets open in 2 hours 34 minutes

AVXL Jan 2024 25.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.65000.0000 (0.00%)
As of 12:55PM EDT. Market open.
Full screen
Previous close2.6500
Open2.6500
Bid2.0000
Ask5.0000
Strike25.00
Expiry date2024-01-19
Day's range2.6500 - 2.6500
Contract rangeN/A
Volume1
Open interest35
  • GlobeNewswire

    Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

    Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter end

  • GlobeNewswire

    Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022

    Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ETNEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial r

  • GlobeNewswire

    Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

    Presentations cover the Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Burden of Illness (BOI) Study in Rett SyndromeNEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other